IP Library Granted Patent US 8,637,506
Granted Patent B2
US 8,637,506 · App. 10/849,067 · Granted Jan 28, 2014

Compositions and methods for bone formation and remodeling

Inventors: Dianqing Wu (Chesire, CT); Yazhou Zhang (Farmington, CT); Peng Liu (West Hartford, CT); Xiaofeng Li (West Hartford, CT); Jie Zhang (Memphis, TN); Jufang Shan (Memphis, TN); Dean Engelhardt (New York, NY)
Assignees: Enzo Biochem, Inc.; University of Connecticut; St. Jude's Childrens Hospital
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,637,506
App. No.
10/849,067
Granted
Jan 28, 2014
Kind
B2
Abstract

The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt.

Claims (3)

1. A method for stimulating or enhancing bone formation or bone remodeling comprising administering at least one compound that binds to or interacts with at least one YWTD domain on the LRP5 or LRP6 receptor, wherein said compound disrupts the binding or interaction of Dkk1 with said YWTD domain and increases Wnt activity as determined by a biological assay, wherein said compound is selected from NCI366218, NCI8642, and NCI657566.

2. The method of claim 1 , wherein a bone fracture, bone disease, bone injury, or bone abnormality is treated.

3. The method of claim 1 , wherein said administering comprises inhalation, oral, intravenous, intraperitoneal, intramuscular, parenteral, transdermal, intravaginal, intranasal, mucosal, sublingual, topical, rectal, or subcutaneous administration, or any combination thereof.

Assignments (6)
CONFIRMATORY LICENSE Recorded Sep 9, 2016
From: UNIVERSITY OF CONNECTICUT
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 039689/0994 →
CONFIRMATORY LICENSE Recorded Sep 9, 2016
From: UNIVERSITY OF CONNECTICUT
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 039981/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2011
From: ZHENG, JIE
To: ST. JUDE'S CHILDRENS HOSPITAL
Reel/Frame 027054/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2011
From: WU, DIANQING (DAN); ZHANG, YAZHOU; LIU, PENG; LI, XIAOFENG
To: CONNECTICUT, THE UNIVERSITY OF
Reel/Frame 027054/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2011
From: SHAN, JUFANG
To: ST. JUDE'S CHILDRENS HOSPITAL
Reel/Frame 027060/0721 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2007
From: ENGELHARDT, DEAN
To: ENZO BIOCHEM, INC.
Reel/Frame 018705/0552 →
Continuity (3)
Provisional Application 60504860 · Sep 22, 2003
Related Publication 20050196349A1 · Sep 8, 2005
Related Publication 20060198791A2 · Sep 7, 2006